Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The global plaque psoriasis (PsO) market was valued at $14.2 billion in 2020 and is projected to record a growth of more than 6% during the forecast period 2021-2030. The major growth drivers of the global PsO market are new product launches, a steady increase in total diagnosed prevalence across the 7MM, and increased treatment options for mild and moderate patients. The major barriers to growth in the PsO market during the forecast period include loss of patent expiry and key biosimilar launches of gold-standard biologics and the launch of apremilast generics.
Global plaque psoriasis market overview
For more insights on this report, download a free report sample
What are the market dynamics in the global plaque psoriasis market?
The PsO affects both sexes and all races, ethnicities, and ages. However, the disease is more prevalent in adults than children. The prevalence of PsO also varies geographically and is more prevalent in countries with higher incomes and regions with older populations. Differences in the reported prevalence between countries may be due to variations in environmental factors and genetic factors. Compared to adults, the pediatric prevalence of PsO in the 7MM was much lower, with 0.17% of boys and 0.24% of girls receiving a diagnosis. The disparity in prevalence between children and adults was observed across all markets. Among children, Japan had the lowest prevalence of PsO in boys. In comparison, France had the highest estimated prevalence with 0.44%, while in girls, the prevalence ranged from 0.06% in Japan to 0.83% in France.
In addition, In the 7MM, the lifetime diagnosed prevalent cases of PsO will increase. In 2020, the US accounted for 47% of lifetime diagnosed prevalent cases of PsO in the 7MM, with 7,477,120 cases, in men and women. Among the 5EU markets, Germany had the greatest number of prevalent cases with 1,747,675 cases, contributing over 10% of lifetime diagnosed prevalent cases of PsO in the 7MM. Conversely, Spain had the lowest number of prevalent cases with 926,456 cases, contributing to over 4% of lifetime diagnosed prevalent cases in 7MM. In 2020, Japan accounted for the lowest percentage of diagnosed prevalent cases of PsO in the 7MM, resulting in 470,089 cases. However, cases in Japan are expected to grow at an Annual Growth Rate (AGR) of over 0.05% to 473,815 cases in 2030. Of the 7MM, the US is expected to see the most significant growth from 7,477,120 lifetimes diagnosed prevalent cases in 2020 to 8,171,859 cases in 2030, occurring at an AGR of over 0.5%. Germany is the only country in the 7MM where cases will decrease between 2020 and 2030, with an ARG of negative 0.04%. This decrease will result in 1,739,834 cases in 2030, down from 1,747,675 cases in 2020. Within the 5EU, France had the highest number of lifetimes diagnosed with prevalent cases of PsO with 2,107,634 cases, while Spain had the fewest with 926,456 cases. In 2030, France will continue to have the most lifetime diagnosed prevalent cases of PsO in the 5EU with 2,185,493 cases, after growing at an AGR of over 0.30%. Likewise, Spain will continue to have the fewest lifetime diagnosed prevalent cases of PsO with 943,870 cases after growing at an AGR of 0.19%.
Which are the key countries in the global plaque psoriasis market?
The US is the largest PsO market, representing over 79% of 2020 global sales. The most notable factor limiting the growth of the market is the loss of several key biologic patents (and anticipated biosimilar launches) across several different classes. Although similar dynamics are expected to be at play for IL-17 inhibitors Cosentyx (secukinumab) and Taltz (ixekizumab), both drugs are expected to remain on patent until the second half of the forecast period, which protects their growth potential for much of the forecast. Additionally, three new IL-17 inhibitors are expected to launch in this market: UCB Pharma’s Bimzelx (bimekizumab), Merck’s sonelokimab, and Affibody’s ABY-035/izokibep. With these factors in mind, the IL-17 inhibitor class sales are expected to grow at a CAGR of over 11%, with combined 2030 sales of over $7 billion. In addition, Combined, the 5EU (France, Germany, Italy, Spain, and the UK) comprised of over 12% of 2020 global sales, with a combined valuation. Across the 5EU, Germany emerged as the highest-grossing country by value in 2020, with estimated PsO sales of over $600 million, followed by the UK, Italy, Spain, and lastly France. Germany is anticipated to remain the highest-grossing market in the 5EU in 2030, generating sales of over $1 billion followed by the UK, Italy, Spain, and lastly France.
Global plaque psoriasis market, by key country
For more regional insights, download a free report sample
Which are the major players in the global plaque psoriasis market?
The major players in the global plaque psoriasis market are AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy’s Laboratories, Arcutis Biotherapeutics, Affibody, Merck, and Can-Fite BioPharma.
Global plaque psoriasis market, by key players
To know more about key players, download a free report sample
Market report scope
Market value (Year-2020) | $14.2 billion |
Growth rate (CAGR) | >6% |
Base year for estimation | 2020 |
Forecast period | 2021-2030 |
Key Players | AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy’s Laboratories, Arcutis Biotherapeutics, Affibody, Merck, and Can-Fite BioPharma |
Scope
- Overview of PsO including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline PsO market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting PsO therapeutics sales in the 7MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global PsO therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
- The greatest drivers of growth in the global PsO market include the launch of eight new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many 7MM countries.
- The main barriers to growth in the PsO market include the patent expiration of several key biologics and small molecules.
- Among the late-stage innovator pipeline products, three are injectable biologics, three are oral small molecules, and two are topical small molecules.
- The most important unmet needs in the PsO market are increased access to therapies as well as therapies that can target multiple disease domains.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global PsO therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsO market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global PsO therapeutics market from 2020-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Pfizer
Johnson & Johnson (J&J)
Bristol-Myers Squibb
UCB Pharma
Amgen
Novartis
Eli Lilly
Sun Pharma
Dermavant
Arcutis Biotherapeutics
Merck
Dr. Reddy’s Laboratories
Affibody
Can-Fite BioPharma
Table of Contents
Table
Figures
Frequently asked questions
-
What was the size of the global plaque psoriasis market in 2020?
The global plaque psoriasis market was valued at $14.2billion in 2020.
-
What is the growth rate of the global plaque psoriasis market?
The global plaque psoriasis market is projected to record a growth of more than 6% during the forecast period 2021-2030.
-
Who are the major players in the global plaque psoriasis market?
The major players in the global plaque psoriasis market are AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy’s Laboratories, Arcutis Biotherapeutics, Affibody, Merck, and Can-Fite BioPharma.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.